AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

• Laura Torres Miñana

  Autor

Participantes ajenos a IIS La Fe

• Daver N.
• Aribi A.
• Martinelli G.
• Altman J.K.
• Wang E.S.
• Roboz G.J.
• Burke P.W.
• Gaidano G.
• Walter R.B.
• Thomas X.
• Jeyakumar D.
• DeAngelo D.J.
• Erba H.P.
• Todisco E.
• Begna K.
• Advani A.
• Gastaud L.
• de la Fuente A.
• Curti A.
• Mendez L.M.
• Vyas P.
• Boissel N.
• Vey N.
• Recher C.
• Longval T.
• Platzbecker U.
• Kapp-Schwörer S.
• Schliemann C.
• Konopleva M.
• Sallman D.A.
• Marcucci G.
• Marconi G.
• Kantarjian H.
• Sloss C.M.
• Malcolm K.E.
• Zweidler-McKay P.A.
• Sweet K.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible

Keywords

• azacitidine; CD135 antigen; chemokine receptor CCR; dexamethasone; isocitrate dehydrogenase 2; pivekimab sunirine; protein p53; venetoclax; WT1 protein; acute myeloid leukemia; aged; antileukemic activity; Article; cancer combination chemotherapy; cancer patient; chill; chromosome 7q; chromosome aberration; clinical article; clinical trial; cohort analysis; drug dose escalation; drug safety; gene deletion; gene mutation; human; infusion related reaction; leukemia relapse; leukemia remission; monosomy 7; overall response rate; premedication; single drug dose; tachycardia; triplet chemotherapy